Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (> 5 years) LEUKEMIA & LYMPHOMA Medeiros, B. C., Minden, M. D., Schuh, A. C., Schimmer, A. D., Yee, K., Lipton, J. H., Messner, H. A., Gupta, V., Chun, K., Xu, W., Das, P., Kamel-Reid, S., Brandwein, J. M. 2007; 48 (1): 65-71

Abstract

The clinical characteristics and outcome of 15 patients with acute myelogenous leukemia (AML) who experienced relapse at least 5 years after induction of complete remission (very late-relapse AML) are described. This subgroup represented 3% of all relapsed patients seen at this institution over the same time period. There were eight males in this cohort and the median age at diagnosis was 48 years (range 13 - 77 years). Nine patients had M4/M5 French - American - British (FAB) classification subtype and most had intermediate risk cytogenetics. The median duration of first complete remission (CR-1) was 9 years (range 5.2 - 11.5 years). Thirteen patients (86%) achieved CR-2 with reinduction therapy. The 5-year relapse-free survival and overall survival rates of this cohort were 59% and 51%, respectively. We conclude that very late-relapse AML is a rare event, and that reinduction in these patients is associated with very high CR rates and a potential cure fraction.

View details for DOI 10.1080/10428190601043252

View details for Web of Science ID 000244249900011

View details for PubMedID 17325849